Effect of low-dose oral contraceptives on androgenic markers and acne

Contraception

Volumn 60, Issue 5, 1999, Pages 255-262

  Thorneycroft, Ian H ^a   Stanczyk, Frank Z ^b   Bradshaw, Karen D ^c   Ballagh, Susan A ^d   Nichols, Mark ^e   Weber, Margaret E ^f  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Wyeth Ayerst Laboratories   (United States)

Author keywords

Acne; Alesse; Androgens; Bioavailable testosterone; Levonorgestrel; Loestrin; Norethindrone acetate; Oral contraceptives; Sex hormone binding globulin

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FERROUS FUMARATE; LOW DOSE ORAL CONTRACEPTIVE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ACNE; ADRENAL GLAND; ADULT; ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MULTICENTER STUDY; NORMAL HUMAN; ORAL CONTRACEPTION; OVARY; RANDOMIZED CONTROLLED TRIAL;

ACNE; AMERICAS; ANDROGENS; BIOLOGY; CALIFORNIA; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE METHODS; DERMATITIS; DEVELOPED COUNTRIES; DISEASES; ENDOCRINE SYSTEM; FAMILY PLANNING; HORMONES; LEVONORGESTREL; NORETHINDRONE; NORETHINDRONE ACETATE; NORTH AMERICA; NORTHERN AMERICA; ORAL CONTRACEPTIVES; PHYSIOLOGY; RESEARCH REPORT; TESTOSTERONE; UNITED STATES;

ACNE VULGARIS; ADOLESCENT; ADRENAL GLANDS; ADULT; ANDROGENS; CONTRACEPTIVES, ORAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; NORETHINDRONE; OVARY; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; WEIGHT GAIN;

EID: 0033368614     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00093-1     Document Type: Article

References (39)

1. Burkman RT Jr. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 1995;98(suppl 1A):130-6S.
2. Wild R.A., Grubb B., Hartz A., Van Nort J.J., Bachman W., Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril. 54:1990;255-259.
3. Dahlgren E., Johansson S., Lindstedt G., et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965 a long-term follow-up focusing on natural history and circulating hormones . Fertil Steril. 57:1992;505-513.
4. Azziz R., Gay F. The treatment of hyperandrogenism with oral contraceptives. Semin Reprod Endocrinol. 7:1989;246-254.
5. Murphy A.A., Cropp C.S., Smith B.S., Burkman R.T., Zacur H.A. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril. 53:1990;35-39.
6. van der Vange N, Blankenstein M.A., Kloosterboer H.J., Haspels A.A., Thijssen J.H.H. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 41:1990;345-352.
7. Jung-Hoffmann C., Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol. 156:1987;199-203.
8. Lemay A., Dewailly D., Grenier R., Huard J. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethinyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab. 71:1990;8-14.
9. Cullberg G., Hamberger L., Mattsson L.-A., Mobacken H., Samsioe G. Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens, and sex hormone binding globulin in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 64:1985;195-202.
10. Dewis P., Petsos P., Newman M., Anderson D.C. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. Clin Endocrinol. 22:1985;29-36.
11. Wieland R.G., Zorn E.M., Hallberg M.C. Differential studies on the mechanism of serum androgen and androgen-binding abnormalities in hirsutism. Am J Obstet Gynecol. 117:1973;983-986.
12. El Makhzangy M.N., Wynn V., Lawrence D.M. Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin Endocrinol. 10:1979;39-45.
13. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin recent advances . Endocrinol Rev. 11:1990;80-91.
14. Darney P.D. The androgenicity of progestins. Am J Med. 98:(suppl 1A):1995;104S-110S.
15. Lucky A.W., Henderson T.A., Olson W.H., Robisch D.M. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 37:(5 Pt 1):1997;746-754.
16. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Acta Obstet Gynecol Scand Suppl. 134:1986;29-32.
17. Palatsi R., Reinila M., Kivinen S. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin, and cortisol before and after oral contraceptive treatment in female acne. Acta Derm Venereol. 66:1986;225-230.
18. Palatsi R., Hirvensalo E., Liukko P., et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol. 64:1984;517-523.
19. Redmond G.P., Olson W.H., Lippman J.S., Kafrissen M.E., Jones T.M., Jorizzo J.L. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris a randomized, placebo-controlled trial . Obstet Gynecol. 89:1997;615-622.
20. Olson W.H., Lippman J.S., Robisch D.M. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil. 43:1998;286-290.
21. Wishart J.M. An open study of Triphasil and Diane 50 in the treatment of acne. Australas J Dermatol. 32:1991;51-54.
22. Anderson F.D. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. Acta Obstet Gynecol Scand Suppl. 71:(suppl 156):1992;15-21.
23. Thiboutot D.M. Acne. An overview of clinical research findings. Dermatol Clin. 15:1997;97-109.
24. Guy R., Green M.R., Kealey T. Modeling acne in vitro. J Invest Dermatol. 106:1996;176-182.
25. Guy R., Kealey T. Modelling the infundibulum in acne. Dermatology. 196:1998;32-37.
26. Thiboutot D., Harris G., Iles V., Cimis G., Gilliland K., Hagari S. Activity of the type 1 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 105:1995;209-214.
27. Paulson R.J., Serafini P.C., Catalino J.A., Lobo R.A. Measurements of 3α,17β-androstanediol glucuronide in serum and urine and the correlation with skin 5α-reductase activity. Fertil Steril. 46:1986;222-226.
28. Lucky A.W., Barber B.L., Girman C.J., Williams J., Ratterman J., Waldstreicher J. A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol. 35:1996;559-565.
29. Goebelsmann U., Horton R., Mestman J.H., et al. Male pseudohermaphroditism due to testicular 17β-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 36:1973;867-879.
30. Goebelsmann U., Arce J.J., Thorneycroft I.H., Mishell D.R. Jr. Serum testosterone concentrations in women throughout the menstrual cycle and following hCG administration. Am J Obstet Gynecol. 119:1974;445-452.
31. Serafini P., Ablan F., Lobo R.A. 5-reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab. 60:1985;349-355.
32. Stanczyk F.Z., Chang L.C., Carmina E., Putz Z., Lobo R.A. Is 11β-hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate? Am J Obstet Gynecol. 165:1991;1837-1842.
33. Wong I.L., Morris S.A., Chang L., Spahn M.-A., Stanczyk F.Z., Lobo R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab. 80:1995;233-238.
34. Cassidenti D.L., Pike M.C., Vijod A.G., Stanczyk F.Z., Lobo R.A. A reevaluation of estrogen status in postmenopausal women who smoke. Am J Obstet Gynecol. 166:1992;1444-1448.
35. Stumpf P.G., Nakamura R.M., Mishell D.R. Jr. Changes in physiologically free circulating estradiol and testosterone during exposure to levonorgestrel. J Endocrinol Metab. 52:1981;138-143.
36. Charoenvisal C., Thaipisuttikul Y., Pinjaroen S., Krisanapan O., Benjawang W. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil. 41:1996;423-429.
37. Lobo RA, Carmina E. Androgen excess. In: Lobo RA, Mishell DR Jr, Paulson RJ, Shoupe D, eds. Mishell's Textbook of Infertility, Contraception and Reproductive Endocrinology, 4th ed. Malden, MA: Blackwell Science, 1997:342-62.
38. Rosenberg M., Waugh M.S. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol. 180:(suppl):1999;S276-S279.
39. Newton J.R. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update. 1:1995;231-263.